		Project Site	Date of First	
Ethics Committee Ref	Project Title	R&D Submission	Patient Consented	Benchmark Met or Reason for Delay
13/NW/0320	MCRN235 (WA28117)	24/06/2013		Benchmark met
13/NW/0321	MCRN234 (WA28118)	24/06/2013		Benchmark met
15,,0521	Weilles I (Willeste)	2 1,00,2010	10,01,2010	Delays due to external factors outside the
12/LO/1876	COBRIM - GO28141	28/06/2013	27/11/2013	control of the Sponsor and Trust
12/NW/0641	NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma	18/07/2013		Benchmark met
12/11/00-11	Techtivia 2 Britis 6. Vernararenio in adjavant melanoma	10/07/2013	07/00/2013	Delays due to external factors outside the
13/SC/0213	ACT IV Study - Protocol CDX110-04	18/07/2013	24/12/2013	control of the Sponsor and Trust
13/SC/0213	VX12-809-104 Lumacaftor + Ivacaftor in Cystic Fibrosis	13/08/2013		Benchmark met
12/WA/1064	ZEST ZEST	07/08/2013		Reasons for delay rest with the Trust
12/ 11/ 1004	Extension study of GS-7977 in patients with HCV infection (GS-	07/00/2013	10/12/2013	neasons for acity rest with the trust
12/EE/0400	US-334-0109)	08/08/2013	00/10/2013	Benchmark met
13/WM/0231	SNIFFLE Study	03/09/2013		Benchmark met
23/ ** *	SWITE Study	03/03/2013	01/10/2013	Delays due to external factors outside the
13 //// /0101	CCRN 2088 (Pneumonia)	22/08/2013		control of the Sponsor and Trust
13/WA/0101	CCRR 2000 (Friedmonia)	22/00/2013		control of the Sponsor and Trust
13/NW/0464	CCPN 2274 (Liver failure)	20/09/2012	21/01/2014	Reasons for delay rest with the Sponsor
13/11/0//0404	CCRN 2274 (Liver failure)	30/08/2013	21/01/2014	Delays due to external factors outside the
40/114202/04	TREC	00/00/2012	07/04/2044	
10/H1202/81	TREC	09/09/2013	07/01/2014	control of the Sponsor and Trust
44 /514 /0227		40/00/2040	07/04/2044	Reasons for delay rest with both sponsor
11/EM/0237	IVICA: Intravenous iron in colorectal cancer associated anaemia	10/09/2013	07/04/2014	
12 /11/2 /22 :-	NeoSCOPE: Neoadjuvant - Study of Chemoradiotherapy in	0.4/00/2003	20/6:/20:-	Delays due to external factors outside the
12/WA/0345	OesoPhagEal Cancer	04/09/2013		control of the Sponsor and Trust
12/YH/0404	CE-MARC 2	23/09/2013		Benchmark met
13/EM/0331	PA for the management of fatigue in RA (FRAPA)	23/09/2013		Benchmark met
11/SS/0100	FOCUS - Fluoxetine Or Control Under Supervision	24/09/2013	01/10/2013	Benchmark met
	MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C			Delays due to external factors outside the
12/EE/0257	Infection (MK5172-047)	24/09/2013	08/01/2014	control of the Sponsor and Trust
	PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment			
13/EM/0254	due to VEGF driven Macular Oedema (CRFB002G2302)	23/09/2013		Benchmark met
13/EE/0263	MASTER II Trial	20/09/2013	15/10/2013	Benchmark met
				Delays due to external factors outside the
13/LO/0418	SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	23/08/2013		control of the Sponsor and Trust
13/SC/0211	Adjunctive Clindamycin for Cellulitis: C4C Trial	25/09/2013	22/10/2013	Benchmark met
				Reasons for delay rest with both sponsor
13/WM/0017	Select-d	25/09/2013	28/01/2014	
13/ES/0005				Delays due to external factors outside the
	NCRN525 (AZACITIDINE + BSC v PLACEBO + BSC)	27/08/2013	22/04/2014	control of the Sponsor and Trust
				Delays due to external factors outside the
11/NW/0075	Lung ART	09/10/2013		control of the Sponsor and Trust
	Oral vs Intravenous Antibiotics (OVIVA) for Bone and Joint			
13/SC/0016	Infection	10/10/2013	21/10/2013	Benchmark met
	MCRN 2419: KOGNITO (Kuvan®'s effect on the cOGNITion of			Delays due to external factors outside the
13/LO/0945	children with phenylketOnuria)	24/09/2013	28/01/2014	control of the Sponsor and Trust
				Delays due to external factors outside the
12/LO/0639	A-PREDICT	11/10/2013		control of the Sponsor and Trust
10/H0802/13	The HOT-KID study	04/11/2013	20/03/2014	Reasons for delay rest with the Trust
				Delays due to external factors outside the
12/LO/1319	UKALL60+	05/11/2013		control of the Sponsor and Trust
	(RAFT) Reducing Arthritis Fatigue - clinical Teams using cognitive-			
13/EE/0310	behavioural approaches	13/11/2013	07/01/2014	Benchmark met
				Delays due to external factors outside the
12/LO/1109	PROMPTS	20/11/2013		control of the Sponsor and Trust
	ROCHE PHASE I SINGLE ASCENDING DOSE Study of RO6867461			
13/NE/0294	in wAMD	18/11/2013	10/01/2014	Benchmark met
				Delays due to external factors outside the
13/YH/0136	CCRN 2173 (Al Liver Decompensation)	16/10/2013		control of the Sponsor and Trust
-, -,	PROSTVAC - Efficacy study of PROSTVAC vaccine in patients with			
-, -,		18/10/2013	28/01/2014	Reasons for delay rest with the Sponsor
GTAC185	prostate cancer	10/10/2013		
	·	16/10/2013	-,-,-	
	prostate cancer	18/10/2013		Delays due to external factors outside the
	prostate cancer ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2			Delays due to external factors outside the control of the Sponsor and Trust
GTAC185	prostate cancer ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-	22/11/2013		
GTAC185 13/LO/0615	prostate cancer ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-	22/11/2013	18/02/2014	control of the Sponsor and Trust
GTAC185	prostate cancer ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum- Resistant Recurrent Ovarian Cancer		18/02/2014	control of the Sponsor and Trust Reasons for delay rest with the Sponsor
GTAC185 13/LO/0615 12/NW/0513	prostate cancer ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum- Resistant Recurrent Ovarian Cancer SALVO	22/11/2013 13/12/2013	18/02/2014 24/02/2014	control of the Sponsor and Trust Reasons for delay rest with the Sponsor Delays due to external factors outside the
GTAC185 13/LO/0615 12/NW/0513 11/MRE00/1	prostate cancer ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum- Resistant Recurrent Ovarian Cancer SALVO EORTC 26091 (TAVAREC)	22/11/2013 13/12/2013 16/12/2013	18/02/2014 24/02/2014 14/05/2014	control of the Sponsor and Trust Reasons for delay rest with the Sponsor Delays due to external factors outside the control of the Sponsor and Trust
GTAC185 13/LO/0615 12/NW/0513 11/MRE00/1 13/LO/1283	prostate cancer ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum- Resistant Recurrent Ovarian Cancer SALVO EORTC 26091 (TAVAREC) MO 28037 - TAMIGA	22/11/2013 13/12/2013 16/12/2013 16/12/2013	18/02/2014 24/02/2014 14/05/2014 20/02/2014	control of the Sponsor and Trust Reasons for delay rest with the Sponsor Delays due to external factors outside the control of the Sponsor and Trust Benchmark met
GTAC185 13/LO/0615 12/NW/0513 11/MRE00/1 13/LO/1283 11/SW/0036	prostate cancer ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum- Resistant Recurrent Ovarian Cancer SALVO EORTC 26091 (TAVAREC) MO 28037 - TAMIGA TABLET	22/11/2013 13/12/2013 16/12/2013 16/12/2013 18/01/2014	18/02/2014 24/02/2014 14/05/2014 20/02/2014 23/01/2014	control of the Sponsor and Trust Reasons for delay rest with the Sponsor Delays due to external factors outside the control of the Sponsor and Trust Benchmark met Benchmark met
GTAC185 13/LO/0615 12/NW/0513 11/MRE00/1 13/LO/1283	prostate cancer ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum- Resistant Recurrent Ovarian Cancer SALVO EORTC 26091 (TAVAREC) MO 28037 - TAMIGA	22/11/2013 13/12/2013 16/12/2013 16/12/2013	18/02/2014 24/02/2014 14/05/2014 20/02/2014 23/01/2014	control of the Sponsor and Trust Reasons for delay rest with the Sponsor Delays due to external factors outside the control of the Sponsor and Trust Benchmark met

Ethics		Project Site R&D	Date of First Patient	
Committee Ref	Project Title	Submission	Consented	Benchmark Met or Reason for Delay
13/WA/0269	CCRN 771 (Endometriosis-related pain)	30/01/2014		Benchmark met
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			, , .	Reasons for delay rest with both sponsor
12/EE/0071	CCRN 923 (Ascites)	20/11/2013	20/05/2014	·
, , ,		-, , -	-,,	Delays due to external factors outside the
10/H0306/61	Platelets for Neonatal Transfusion Study	17/02/2014	08/06/2014	control of the Sponsor and Trust
	Continuation Study of Prophylactic BAX 855 in PTP with		, ,	,
14/NW/0001	Haemophilia A	17/02/2014	13/03/2014	Benchmark met
13/NW/0002	CCRN 1073 (Thoracic aortic surgery)	06/02/2014		Benchmark met
	Developing a new drug to treat infants hospitalised with RSV		, ,	Delays due to external factors outside the
14/WM/0013	infection	24/02/2014		control of the Sponsor and Trust
13/SW/0300	CoolXenon3	21/02/2014		Benchmark met
13/YH/0229	GO2	19/02/2014		Benchmark met
., ,,====	MAESTRO: Macitentan in Eisenmenger Syndrome AC-055-305		, ,	Delays due to external factors outside the
13/LO/0161	(CCRN 2104)	28/02/2014		control of the Sponsor and Trust
25, 25, 0101	SAPROCAN: Saracatnib and docetaxel in met, cast-ref prostate			
11/AL/0081	cancer	10/03/2014	24/04/2014	Benchmark met
14/EM/0001	TREND (CRFB002A2411)	11/03/2014		Benchmark met
	M12-813: Elagolix in Premenopausal Women with Heavy		, ,	
13/EE/0377	Menstrual Bleeding Associated with Uterine Fibroids	13/03/2014	22/05/2014	Benchmark met
-, ,	3	-,,	, , .	Delays due to external factors outside the
13/WS/0304	EVARREST (The Fibrin Pad CV Phase III Study)	17/03/2014		control of the Sponsor and Trust
-, -,		,		Delays due to external factors outside the
13/SW/0186	EFFECT - Efficacy of Fluticasone/Formoterol in COPD Treatment	11/03/2014		control of the Sponsor and Trust
12/LO/1078	MUK five	20/03/2014		Reasons for delay rest with the Sponsor
				Delays due to external factors outside the
13/YH/0020	MCRN222 (MCI-196-E14)	11/03/2014		control of the Sponsor and Trust
	(
12/LO/1717	ZEBRA	26/03/2014		Reasons for delay rest with the Sponsor
12/SS/0138	RESTART study	26/03/2014	20/05/2014	Benchmark met
12/33/0130	Vasopressin vs Noradrenaline as Initial therapy in Septic Shock	20,03,2014	20/03/2014	Deficilitate free
12/SC/0014	(Vanish)	03/04/2014	05/06/2014	Benchmark met
13/NE/0049	MCRN224 (BAY 94-9027)	28/03/2014		Benchmark met
13/112/00-13	Mem224 (5/11 54 5027)	20,03,2014	03/00/2014	benefittark mee
13/YH/0152	FIGARO	21/03/2014		Reasons for delay rest with the Sponsor
13/11/0132	ACORN - Improving diagnosis with endocervical curettage and	21/03/2014		neasons for delay rest with the Sponsor
14/SW/0028	P16 staining	07/04/2014	06/05/2014	Benchmark met
13/SC/0111	FOCUS 4	09/04/2014		Benchmark met
13/NI/0143	SIEGE	02/04/2014		Benchmark met
13/11/0143	JETREA FIRSTLINE (ALCON) - Assessment of Patients Treated	02/04/2014	25/05/2014	Deficilitate frice
14/SC/0100	With JETREA® for Vitreomacular Traction	15/04/2014	03/06/2014	Benchmark met
12/LO/0145	DRN 840 (CLEOPATRA)	29/04/2014		70 days not yet reached
GTAC182	TRIOC	30/04/2014		Benchmark met
14/SW/0079	CCRN - 3308 The DEFLECT III Trial	11/05/2014		Benchmark met
±-7/300/3	COAST BAY73-4506/15983: Regorafenib as adjuvant therapy for	11,03,2014	13/03/2014	Denominary met
13/NW/0705	resected liver metastases	12/05/2014		70 days not yet reached
14/LO/0036	NCRN2555 - TOWER Study (00103311)	29/04/2014		70 days not yet reached
14/10/0030	PREVENTT (Preoperative intravenous iron to treat anaemia in	23/04/2014		70 days not yet reached
12/EE/0445		12/05/2014		70 days not yet reached
12/EE/0445 13/NW/0609	major surgery) Alight (AMD light trial)	12/05/2014		70 days not yet reached 70 days not yet reached
	0 , 0 ,	12/05/2014		, ,
13/LO/0551	PEPtalk 2	12/05/2014		70 days not yet reached
13/YH/0201	MCRN2280 Sativex Severe Spasticity (GWSP08258)	06/05/2014		70 days not yet reached
11/YH/0290	STOMP	01/05/2014		70 days not yet reached
12/WA/0230	POCC. Redicth are no offer Constitution of Con	00/00/200		70 days not ust (
	ROCS: Radiotherapy after Oesophageal Cancer Stenting Study	09/06/2014		70 days not yet reached
42 /41/0426	GWCA1208 - Study of Sativex in Patients with Recurrent	06/06/2011		70 days a shoot as a shoot
13/YH/0126	Glioblastoma	06/06/2014		70 days not yet reached
12/NW/0827	Euro Ewing 2012	09/06/2014		70 days not yet reached
13/NE/0197	RDP Trial (Ranibizumab for DMO PRP trial)	09/06/2014		70 days not yet reached
14/SW/0007	An expressive writing study for breast cancer patients.	12/06/2014		70 days not yet reached
10/H0203/70	Fluid Management in 10-15% BSA scalds	12/06/2014		70 days not yet reached
14/YH/0007	MCRN2368 UCB PRA Epilepsy Lacosamide SP0969	12/06/2014		70 days not yet reached
14/WS/0004	Odyssey OLE	30/05/2014		70 days not yet reached
13/SC/0557	THAPCA-IH-UK	17/06/2014		70 days not yet reached